Wolverine Trading
AKBA icon

Wolverine Trading’s Akebia Therapeutics AKBA Stock Holding History

Wolverine Trading’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,900
Closed -$35K – 4671
2024
Q4 		$35K Buy
+18,900
New +$32.8K ﹤0.01% 5048
2024
Q2 		– Sell
-36,200
Closed -$66.2K – 4405
2024
Q1 		$66.2K Buy
36,200
+26,200
+262% +$41.9K ﹤0.01% 4153
2023
Q4 		$12.4K Buy
+10,000
New +$10.2K ﹤0.01% 4398
2023
Q3 		– Sell
-14,600
Closed -$13.5K – 4426
2023
Q2 		$13.5K Buy
+14,600
New +$14.1K ﹤0.01% 4122
2021
Q3 		– Sell
-15,300
Closed -$59K – 6197
2021
Q2 		$59K Sell
15,300
-13,300
-47% -$44.8K ﹤0.01% 5569
2021
Q1 		$89K Buy
28,600
+4,400
+18% +$15.8K ﹤0.01% 5478
2020
Q4 		$72K Buy
24,200
+6,800
+39% +$19.9K ﹤0.01% 4545
2020
Q3 		$42K Buy
+17,400
New +$153K ﹤0.01% 4300
2020
Q2 		– Sell
-18,400
Closed -$146K – 4502
2020
Q1 		$146K Sell
18,400
-11,900
-39% -$92.6K ﹤0.01% 3839
2019
Q4 		$199K Buy
30,300
+18,500
+157% +$87.9K ﹤0.01% 4025
2019
Q3 		$49K Sell
11,800
-13,900
-54% -$59.6K ﹤0.01% 4051
2019
Q2 		$124K Sell
25,700
-3,500
-12% -$19.9K ﹤0.01% 3932
2019
Q1 		$239K Buy
29,200
+800
+3% +$5.49K ﹤0.01% 3624
2018
Q4 		$153K Buy
+28,400
New +$222K ﹤0.01% 3820

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's AKBA Position: Q3 2023 in Review

Wolverine Trading sold out of Akebia Therapeutics (AKBA) in Q3 2023, closing a stake of 20,198 shares — an estimated $25.9K sold.

Wolverine Trading first reported a position in AKBA in Q2 2019 and held it in 10 quarters. The position peaked at $153K in Q2 2020. 76 funds tracked by Wall St. Rank hold AKBA as of Q3 2023.

  • Wolverine Trading reported no remaining Akebia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Wolverine Trading sold 20,198 Akebia Therapeutics shares in Q3 2023, an estimated $25.9K.
  • Wolverine Trading first reported a position in Akebia Therapeutics in Q2 2019 and held it in 10 quarters.
  • Wolverine Trading's Akebia Therapeutics position peaked at $153K in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2023.

Based on Wolverine Trading's 13F filing for Q3 2023, filed 15 Nov 2023.